arrow_rightarrow_righticon_excelicon_pficon_ppticon_wordmagnifier

Scientific Programme

Thursday 11 Nov

12:30

Welcome

Session 1: From basic science to clinical application

Chair: Jan B. Vermorken (BE)

13:00

The gut microbiota and anticancer immunotherapy

Laurence Zitvogel (F)

13:25

The bidirectional communication between tumor cells and other components of the tumor microenvironment

Phil Sloan (UK)

13:50

Resistance mechanisms in immune checkpoint inhibitors and radiotherapy and how to overcome this

Kirsten Lauber (DE)

14:15

DNA repair mechanisms as a new target in head and neck cancer

Kevin Harrington (UK)

14:40

Break and poster viewing

15:10

How to standardize molecular profiling programs for routine patient care

Ingeborg Tinhofer (DE)

15:35

Novel immune oncology targets beyond PD-1/PD-L1 in head and neck cancer

Christophe Le Tourneau (F)

16:00

Analytic methods to understand head and neck cancer evolution to guide therapeutic approaches

Ben O’Leary (UK)

16:25

Proffered paper session

Chaired by René Leemans

O01: Delay in the presentation of head and neck cancer in Scotland
following the COVID-19 pandemic
William Flynn (UK)

O02: Preclinical Implementation of a Steerable, Da Vinci Xi ®
Compatible CO2-Laser Fiber Carrier for Transoral Robotic Surgery (TORS):
a Cadaveric Feasibility Study
Jeroen Meulemans (BE)

O03: Dental status and weight loss in locally advanced oropharyngeal cancer
Doke Buurman (NL)

O04: Ultrasound-guided resection of tongue cancer
Klijs De Koning (NL)

17:30

Clinical cases: Panel discussion

chaired by Jean Pascal Machiels

Panel: René Leemans, Remco de Bree, Volker Budach, Marije Vergeer, Amanda Psyrri, Jan Buter, Pim de Graaf, Phil Sloan

19:00

News from the European Head & Neck Society (EHNS)

Wojciech Golusinski, President EHNS

19:15

Welcome reception

Friday 12 Nov

Session 2: Primary disease

Chair Piero Nicolai (I)

09:00

Sensitivity and specificity of extranodal extension in SCCHN: unlocking the strongest prognostic factor in head and neck cancer

Brian O’Sullivan (CA)

09:25

From photon to proton: what’s in it for head and neck cancer patients?

Volker Budach (DE)

09:50

Lessons learned from RTOG 1016 and DE-ESCALaTE: what’s next?

Hisham Mehanna (UK)

10:15

Break and poster viewing

10:45

Treatment intensification in LA-SCCHN: what are the options and for who?

Jan Vermorken (BE)

11:10

Immune checkpoint inhibitors in the curative setting: preclinical and clinical data

Jean-Pascal Machiels (BE)

11:35

Carcinoma of unknown primary: diagnostics and the potential of transoral surgery

René Leemans (NL)

12:00

Clinical cases: Panel discussion

Chaired by Volker Budach

Panel: René Leemans, Piero Nicolai, Jean-Pascal Machiels, Jan Buter, Brian O’Sullivan, Marije Vergeer, Pim de Graaf, Phil Sloan

13:30

Lunch and sponsored symposium organized by MSD

13:30

Sponsored symposium organized by MSD

To view the programme of the sponsored symposium organized by MSD, click here.

Session 3: Recurrent and/or metastatic (R/M) SCCHN

Chair: Jan Vermorken (BE)

14:30

Individualized therapy in 1-line R/M-SCCHN: what selection criteria should we use?

Petr Szturz (CH)

15:00

Patterns of response to immune oncology drugs: how relevant are they in SCCHN?

Amanda Psyrri (GR)

15:20

The role of radiotherapy in oligometastatic or oligoprogressive disease in R/M-SCCHN

Daan Nevens (BE)

15:45

Break and poster viewing

16:15

Proffered paper session

Chaired by Jean-Pascal Machiels

O05: The added value of the comprehensive geriatric assessment
in the choice of treatment strategy for locally advanced head and
neck cancer patients
Paolo Bossi (IT)

O06: Incorporating immune response into TNM staging of early oral tongue cancer
Alhadi Almangush (FI)

O07: Image-based analysis of skeletal muscle mass predicts
cisplatin dose-limiting toxicity in patients with locally advanced
head and neck cancer
Remco de Bree (NL)

O08: Feasibility, SAR distribution and clinical outcome upon re-irradiation
and deep hyperthermia using the Hypercollar3D in head and neck
cancer patients
Michiel Kroesen (NL)

17:15

News from EORTC-HNCG

Jean-Pascal Machiels

17:30

Keynote lecture: Real world evidence in head and neck cancer

Anil D’Cruz (UICC president)

Saturday 13 Nov

Session 4: Special topics

Chair: Brian O’Sullivan (CA)

09:00

Pathology driven treatment of skull base tumors

Piero Nicolai (I)

09:25

Modern day reconstruction of facial bones

Sat Parmar (UK)

09:50

Targeting molecular/minimal residual disease using novel technologies and clinical trials design

Lillian Siu (CA)

10:15

Break

10:45

New developments in surgery for malignant salivary gland tumors

Jeroen Meulemans (BE)

11:10

New systemic therapies in salivary gland cancer

Athanassios Argiris (GR)

11:35

Exercise and nutrition interventions in head and neck cancer

Paolo Bossi (I)

12:00

Telehealth intervention in head and neck cancer patients: a promise?

Irma Verdonck-de Leeuw (NL)

12:25

General discussion

13:00

Adjourn